Patricia LoRusso
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 8
- PARP inhibition in cancer therapy 7
- Cancer Treatment and Pharmacology 7
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 5
- Hematology top 5%
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 8
- Cancer Genomics and Diagnostics 7
-
- Cancer therapeutics and mechanisms 7
- Co-authors
- Ian E. KropShanu ModiKathy D. MillerHope S. RugoGladys RodriguezEllie GuardinoLukas C. AmlerSandhya Girish
- Journals
- Journal of Clinical Oncology (26 papers)SHILAP Revista de lepidopterología (2 papers)Cancer (1 paper)
- Partner nations
- United StatesJapanSpain
In The Last Decade
Patricia LoRusso
62 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 86
- Oncology 1.1k
- Genetics 213
- Radiology, Nuclear Medicine and Imaging 405
- Hematology 192
- Cancer Research 228
Countries citing papers authored by Patricia LoRusso
This map shows the geographic impact of Patricia LoRusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia LoRusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia LoRusso more than expected).
Fields of papers citing papers by Patricia LoRusso
This network shows the impact of papers produced by Patricia LoRusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia LoRusso. The network helps show where Patricia LoRusso may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Patricia LoRusso, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 11 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 9 | |
| 5 | 2024 | 24 | |
| 6 | 2024 | 9 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 4 | |
| 9 | 2023 | 0 | |
| 10 | 2022 | 19 | |
| 11 | 2013 | 74 | |
| 12 | 2012 | 274 | |
| 13 | 2012 | 91 | |
| 14 | 2011 | 35 | |
| 15 | 2010 | 21 | |
| 16 | 2008 | 152 | |
| 17 | A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis | 2007 | 9 |
| 18 | Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas | 2007 | 1 |
| 19 | 2006 | 2 | |
| 20 | 1988 | 45 |
About Patricia LoRusso
Patricia LoRusso is a scholar working on Oncology, Cancer Research and Genetics, having authored 66 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (8 papers), Cancer, Hypoxia, and Metabolism (8 papers), Cancer therapeutics and mechanisms (7 papers), Cancer Genomics and Diagnostics (7 papers), PARP inhibition in cancer therapy (7 papers), Cancer Treatment and Pharmacology (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Oncology (1.1k citations), Genetics (213 citations) and Radiology, Nuclear Medicine and Imaging (405 citations). Patricia LoRusso has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Ian E. Krop, Shanu Modi, Kathy D. Miller, Hope S. Rugo, Gladys Rodriguez, Ellie Guardino, Lukas C. Amler, Sandhya Girish, Eric P. Winer and Denise A. Yardley. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.